» Articles » PMID: 35054843

Engineering Nanoplatform for Combined Cancer Therapeutics Via Complementary Autophagy Inhibition

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Jan 21
PMID 35054843
Authors
Affiliations
Soon will be listed here.
Abstract

Despite advances in the development of tumor treatments, mortality from cancer continues to increase. Nanotechnology is expected to provide an innovative anti-cancer therapy, to combat challenges such as multidrug resistance and tumor recurrence. Nevertheless, tumors can greatly rely on autophagy as an alternative source for metabolites, and which desensitizes cancer cells to therapeutic stress, hindering the success of any current treatment paradigm. Autophagy is a conserved process by which cells turn over their own constituents to maintain cellular homeostasis. The multistep autophagic pathway provides potentially druggable targets to inhibit pro-survival autophagy under various therapeutic stimuli. In this review, we focus on autophagy inhibition based on functional nanoplatforms, which may be a potential strategy to increase therapeutic sensitivity in combinational cancer therapies, including chemotherapy, radiotherapy, phototherapy, sonodynamic therapy, and immunotherapy.

Citing Articles

Research Progress of Regulatory Cell Death in Coronary Microembolization.

Chang C, Huang W, Cai R, Mo L, Wu Q, Su Q Int J Med Sci. 2025; 22(1):132-139.

PMID: 39744170 PMC: 11659838. DOI: 10.7150/ijms.105295.


The Emerging Landscape for Combating Resistance Associated with Energy-Based Therapies via Nanomedicine.

Hu Q, Zuo H, Hsu J, Zeng C, Tian Z, Sun Z Adv Mater. 2023; 36(5):e2308286.

PMID: 37971203 PMC: 10872442. DOI: 10.1002/adma.202308286.


Mapping knowledge landscapes and emerging trends of sonodynamic therapy: A bibliometric and visualized study.

Wu Z, Cheng K, Shen Z, Lu Y, Wang H, Wang G Front Pharmacol. 2023; 13:1048211.

PMID: 36699067 PMC: 9868186. DOI: 10.3389/fphar.2022.1048211.

References
1.
Bhat P, Kriel J, Shubha Priya B, Basappa , Shivananju N, Loos B . Modulating autophagy in cancer therapy: Advancements and challenges for cancer cell death sensitization. Biochem Pharmacol. 2017; 147:170-182. DOI: 10.1016/j.bcp.2017.11.021. View

2.
Akinleye A, Rasool Z . Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019; 12(1):92. PMC: 6729004. DOI: 10.1186/s13045-019-0779-5. View

3.
Ruan S, Xie R, Qin L, Yu M, Xiao W, Hu C . Aggregable Nanoparticles-Enabled Chemotherapy and Autophagy Inhibition Combined with Anti-PD-L1 Antibody for Improved Glioma Treatment. Nano Lett. 2019; 19(11):8318-8332. DOI: 10.1021/acs.nanolett.9b03968. View

4.
Feng X, Zhang Y, Zhang C, Lai X, Zhang Y, Wu J . Nanomaterial-mediated autophagy: coexisting hazard and health benefits in biomedicine. Part Fibre Toxicol. 2020; 17(1):53. PMC: 7565835. DOI: 10.1186/s12989-020-00372-0. View

5.
Zhang J, Wang G, Zhou Y, Chen Y, Ouyang L, Liu B . Mechanisms of autophagy and relevant small-molecule compounds for targeted cancer therapy. Cell Mol Life Sci. 2018; 75(10):1803-1826. PMC: 11105210. DOI: 10.1007/s00018-018-2759-2. View